The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD)
MA Akkaif, NAA Daud, A Sha'aban, ML Ng… - Molecules, 2021 - mdpi.com
Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention
MS Hasan, HB Basri, LP Hin… - International Journal of …, 2013 - Taylor & Francis
Ischemic heart disease and stroke are the two leading causes of death worldwide.
Antiplatelet therapy plays the most significant role in the management of these …
Antiplatelet therapy plays the most significant role in the management of these …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease …
Objectives: We aimed to test whether cilostazol has beneficial effects in the real-world
patients treated with intracoronary drug-eluting stents (DES). Background: The addition of …
patients treated with intracoronary drug-eluting stents (DES). Background: The addition of …
Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated …
Background—As compared with whites, East Asians more often carry the cytochrome P450
(CYP) 2C19 loss-of-function (LOF) allele with the CYP2C19* 3 variant. The influence of the …
(CYP) 2C19 loss-of-function (LOF) allele with the CYP2C19* 3 variant. The influence of the …
Prevalence of poor biological response to clopidogrel
N Mallouk, C Labruyère, JL Reny… - Thrombosis and …, 2012 - thieme-connect.com
The existence of poor biological response to clopidogrel has been shown in some patients.
Despite the increasing number of studies, this phenomenon remains difficult to quantify. We …
Despite the increasing number of studies, this phenomenon remains difficult to quantify. We …
Association of cytochrome P450 2C19* 2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
Background Although East Asians carry the cytochrome P450 (CYP) 2C19* 2 allele more
frequently than do Caucasians, the impact of the CYP2C19* 2 allele on clopidogrel …
frequently than do Caucasians, the impact of the CYP2C19* 2 allele on clopidogrel …
Effect of the CYP2C19* 2 and* 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in …
XF Tang, J Wang, JH Zhang, XM Meng, B Xu… - European journal of …, 2013 - Springer
Purpose Chinese people are more frequent carriers of cytochrome P450 2C19 (CYP2C19)
loss-of-function alleles than Caucasians. The effect of the ATP-binding cassette, sub-family …
loss-of-function alleles than Caucasians. The effect of the ATP-binding cassette, sub-family …
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis
Z Xi, F Fang, J Wang, J AlHelal, Y Zhou, W Liu - Platelets, 2019 - Taylor & Francis
The effect of CYP2C19 gene polymorphism on clinical outcomes of patients with coronary
artery disease (CAD) treated with clopidogrel remains controversial. Ethnicity has been …
artery disease (CAD) treated with clopidogrel remains controversial. Ethnicity has been …
Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects
T Simon, DL Bhatt, L Bergougnan… - Clinical …, 2011 - Wiley Online Library
A double‐blind crossover study was conducted in four CYP2C19 genotype–defined
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …